Lung cancer—the leading cause of cancer death in men and women worldwide at 1.80 million—is the second most diagnosed cancer in the United States, accounting for approximately a quarter of all cancer deaths. Divided into 2 primary types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), NSCLC comprises nearly 84% of lung cancer, while SCLC constitutes about 13% of lung cancers in the U.S. each year. Although SCLC is less common, it is more aggressive and metastasizes rapidly to organs such as the liver, bones, adrenal glands, the lymph nodes, and the brain. Smoking tobacco is the leading cause for lung cancer, accounting for 90% of all SCLC diagnoses. Current treatments include chemotherapy, radiotherapy, immunotherapy, and surgery. With estimated new lung cancer cases of 235,760 and estimated deaths of 131,880 in 2021, it is imperative to find new ways to overcome treatment barriers in patients with lung cancer.
In early 2021, ACCC began facilitating patient- and provider-facing surveys that focus on creating awareness about the SCLC patient experience. These surveys, used to identify and better comprehend the gaps and potential disconnects in the patient/provider relationship in the treatment of SCLC, highlight opportunities to improve patient care. ACCC's Comprehensive Quality Care for Patients with Small Cell Lung Cancer initiative builds upon those survey findings to help dispel misconceptions and myths about SCLC and its treatment, promoting the use of guideline-concordant treatment plans, and identifying and uncovering the gaps, barriers, and challenges to deliver optimal care to patients with SCLC.
This multi-phased initiative's key learning objectives include:
For more information on this project, please contact the ACCC Provider Education department.
ACCC examined best practices in the treatment of small cell lung cancer. The following cancer programs highlight best practices in specific areas of cancer care.
ACCC engaged in a multi-phased educational initiative to address the challenges and burdens faced by patients with small cell lung cancer in community oncology programs and practices. Read on to learn more about barriers and best practices in treating patients with small cell lung cancer.
With the assistance of its Advisory Committee and Partner Organization, ACCC has developed a curated resource library that incorporates publications, webinars, tools, and other resources for small cell lung cancer treatment.
Access Resource Library
Significant declines in the screening, diagnosis, and treatment of patients with small cell lung cancer have increased challenges that impact patient care. Many patients with small cell lung cancer have a high symptom burden, poor prognosis, adherence challenges due to treatment-related adverse events, stigmatization, and emotional distress. The team at Atrium Health’s Levine Cancer Institute is testing supportive care options with the goal of meeting the needs of all their patients.
Multidisciplinary care coordination is especially important with aggressive cases of SCLC, as there may be several unique challenges to be addressed. Watch now!
CANCER BUZZ spoke to David Waterhouse, MD, MPH, Medical Oncologist and Hematologist at the Dana-Farber Brigham Cancer Center, Milford Regional Medical Center in Milford, MA. Hear how to engage patients in clinical trials and address barriers.
Funding & support provided by AstraZeneca and G1 Therapeutics.